Praxis Precision Medicines公司预计2026年2月中旬前提交两款新药申请:Ulixacaltamide用于特发性震颤及Relutrigine用于SCN2A/8A相关疾病

美股速递
Jan 12

Praxis Precision Medicines公司宣布,针对其在研药物Ulixacaltamide与Relutrigine的两项新药申请(NDA),预计将于2026年2月中旬前提交。其中,Ulixacaltamide的适应症为特发性震颤,而Relutrigine则旨在治疗与SCN2A及SCN8A基因相关的疾病。这一进展标志着公司在推进其精准医疗管线方面迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10